Quoin Pharmaceuticals Ltd... (QNRX)
0.31
-0.05 (-12.73%)
At close: Feb 28, 2025, 3:59 PM
0.30
-3.94%
After-hours: Feb 28, 2025, 05:53 PM EST
Company Description
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases.
The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome.
It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
The company is based in Ashburn, Virginia.
Quoin Pharmaceuticals Ltd.
| Country | United States |
| IPO Date | Aug 1, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Michael Myers Ph.D. |
Contact Details
Address: 42127 Pleasant Forest Court Ashburn, Virginia United States | |
| Website | https://quoinpharma.com |
Stock Details
| Ticker Symbol | QNRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671502 |
| CUSIP Number | 74907L102 |
| ISIN Number | US74907L3006 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, Chief Executive Officer & Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer & Director |
| Gordon Bruce Dunn J.D. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 04, 2025 | 8-K | Current Report |
| Jan 28, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jan 28, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 8-K | Current Report |
| Jan 06, 2025 | 8-K | Current Report |
| Jan 02, 2025 | SCHEDULE 13D | Filing |
| Jan 02, 2025 | SCHEDULE 13D | Filing |